Performance and Safety Evaluation of a Novel Non-invasive Glucose Monitoring Device

Diabetes Mellitus Clinical Trial

Official title:

Performance and Safety Evaluation of a Novel Non-invasive Glucose Monitoring Device

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04031300
• Other study ID #: RSP-20
• Status: Withdrawn
• Phase: N/A
• Start date: June 1, 2019
• Est. completion date: June 1, 2019

Study information

• Verified date: November 2023
• Source: RSP Systems A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pivotal multicenter study has been launched to collect spectral Raman data paired with validated glucose reference values in diabetic patients.

Description:

Participants will be enrolled at six different sites in four different countries. All participants will undergo identical procedures, which include four steps: Baseline visit (1 day), calibration period (25 days), validation period (23 days) and a close-out visit (1 day) with a total duration of 50 days.

The calibration period consists of 23 home-based days and two in-clinic days. At the two in-clinic days, measurement sessions are performed every 30 minutes. A measurement session consists of two reference measurements (Contour Next One) and three measurements on the Investigational Medical Device. The glucose level of the participants is manipulated by administration of a glucose rich drink. At home-based days, the subject must perform four measurement sessions a day. During the validation period, participants perform up to four home-based measurement sessions a day.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 1, 2019
• Est. primary completion date: June 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male and female subjects =18 years of age

• Diagnosed with diabetes, all types except gestational diabetes

• Skin phototype 1-4

• Willing to perform a minimum of 8 finger sticks during each day of home-based measurements and 30 finger sticks at the two in-clinic study days

• Subject has a wireless internet connection at home to be used in the study

Exclusion Criteria:

• For female subjects: Pregnancy or subject is attempting to conceive or not willing and able to practice birth control during the study duration

• For female subjects: Breastfeeding

• Subject currently participating in another study

• Subject not able to understand and read the local language

• In investigator's opinion, subject is not able to follow instructions provided and as specified in the protocol

• Subject not able to hold hand/arm steady (including tremors and Parkinson's Disease)

• Subject diagnosed with cardiovascular diseases

• Reduced circulation in right hand evaluated by Allen's test

• Subjects receiving anticoagulants, active cancer treatment, tetracyclines and other medication/topical agents increasing photosensitivity

• Radiotherapy for the past six months

• Extensive skin changes, tattoos or diseases on right hand thenar (probe application site)

• Known allergy to medical grade alcohol used to clean the skin

• Medical history or any condition that may, in the opinion of the investigator compromise the subject's ability to participate

• Comorbidity or concomitant medical condition which, in the opinion of the Investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• Prototype 0.5
Investigational Medical Device collecting spectral Raman data non-invasively from tissue

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center Copenhagen (SDCC)	Gentofte
Denmark	Steno Diabetes Center Odense (SDCO)	Odense C
Germany	Institut für Diabetes-Technologie Forschungs- und Entwicklungs-gesellschaft mbH an der Universität Ulm (IDT)	Ulm
Sweden	Sahlgrenske University Hospital (SUH)	Gothenburg
Sweden	Department of Medicine, Uddevalla Hospital (UVH)	Uddevalla
United Kingdom	University Hospitals Birmingham (UHB)	Birmingham

Sponsors (1)

Lead Sponsor	Collaborator
RSP Systems A/S

Countries where clinical trial is conducted

Denmark,  Germany,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement accuracy	Accuracy of measurements performed on the IMD will be evaluated by data from subjects. Data will be analyzed by Mean Absolute Relative Difference (MARD).	6 months
Primary	Safety evaluation: paucity of adverse events	Safety of the IMD will be evaluated in a descriptive manner by the paucity of adverse events reported during the clinical study	6 months
Secondary	Device deficiencies	Description of device deficiencies will be listed. Deficiencies will be reported during the clinical study.	Up to 6 months
Secondary	Device usability	The use of the device will be evaluated by means of questionnaires. The subjects are asked if they encountered any problems during measurements, and if so, to elaborate the problems encountered.	6 months